These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 38194216)

  • 1. Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours.
    Fuller-Shavel N; Krell J
    Curr Oncol Rep; 2024 Feb; 26(2):164-174. PubMed ID: 38194216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.
    Malczewski AB; Ketheesan N; Coward JIG; Navarro S
    Front Immunol; 2021; 12():624434. PubMed ID: 34305883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
    Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
    Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
    Michielin O; Lalani AK; Robert C; Sharma P; Peters S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gut wall's potential as a partner for precision oncology in immune checkpoint treatment.
    Hone Lopez S; Jalving M; Fehrmann RSN; Nagengast WB; de Vries EGE; de Haan JJ
    Cancer Treat Rev; 2022 Jun; 107():102406. PubMed ID: 35569388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
    Delaye M; Rousseau A; Mailly-Giacchetti L; Assoun S; Sokol H; Neuzillet C
    Pharmacol Ther; 2023 Jul; 247():108442. PubMed ID: 37210004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era.
    Spyrou N; Vallianou N; Kadillari J; Dalamaga M
    Semin Cancer Biol; 2021 Aug; 73():356-376. PubMed ID: 33989733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!
    Shouman M; Goubran H; Seghatchian J; Burnouf T
    Transfus Apher Sci; 2023 Apr; 62(2):103685. PubMed ID: 36870904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy.
    Yoon SJ; Lee CB; Chae SU; Jo SJ; Bae SK
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive supportive care program for fine-tuning cancer immunotherapy.
    de Borms AT; Colard-Thomas J; Laurent PI; Coget E; Carbasse C; Annakib S; Thomas QD; Nicolas E; Fiteni F
    Support Care Cancer; 2024 Jun; 32(7):452. PubMed ID: 38907798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
    Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the
    Nishino M
    AJR Am J Roentgenol; 2022 Jan; 218(1):19-27. PubMed ID: 33594904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
    Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
    Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Know thyself' - host factors influencing cancer response to immune checkpoint inhibitors.
    Gunjur A; Manrique-Rincón AJ; Klein O; Behren A; Lawley TD; Welsh SJ; Adams DJ
    J Pathol; 2022 Jul; 257(4):513-525. PubMed ID: 35394069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.